Jia Jenny Liu, Translational Lead of Early Phase Drug Development at The Kinghorn Cancer Centre, shared a post on LinkedIn:
“ASCO is where we often celebrate the next breakthrough.
But this review asks what happens after the breakthrough, and why scientific advances do not always translate into patient benefit in the real world.
Published today in Journal of Clinical Oncology, in the middle of ASCO26:
Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation
Tumor-agnostic therapies have changed the logic of cancer treatment: from where a cancer starts, to what molecular feature may be driving it.
But they also expose a central tension in modern oncology:
The science can be global.
The access is not.
With co-authors across 5 continents and 9 countries/jurisdictions, we examine the global implementation challenges of tumor-agnostic therapies and propose a framework spanning biology, clinical-trial evidence, approval/access, and real-world implementation.
The key message is simple:
Approval is not access.
Access requires testing infrastructure, trial pathways, reimbursement, workforce capability, decision support, and systems that can move patients from a molecular result to a treatment opportunity.
Precision oncology now needs to mature beyond targets and approvals.
It needs better systems to ensure patients can actually reach the therapies we are developing.
Grateful to my co-authors and collaborators for helping shape this global perspective: Juliana Rodrigues Beal, Niamh Coleman, Brigette B.Y. Ma, Herbert Loong, MBBS FRCP FASCO, Hongyun Zhao, Lesley Seymour, Benedikt Westphalen, Giuseppe Curigliano and the visionary leadership and mentorship of Vivek Subbiah, MD.”
Title: Tumor-Agnostic Therapies: Translating Scientific Breakthroughs Into Global Implementation
Authors: Jia Liu, Juliana Beal, Niamh Coleman, Brigette B.Y. Ma, Herbert H. Loong, Hongyun Zhao, Lesley Seymour, Christoph Benedikt Westphalen, Giuseppe Curigliano, Vivek Subbiah
Other articles featuring Jia Jenny Liu on OncoDaily.
